Karyopharm Therapeutics Announces Board and Executive Changes
Ticker: KPTI · Form: 8-K · Filed: Jan 31, 2025 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Jan 31, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
Related Tickers: KPTI
TL;DR
Karyopharm's board is shuffling, with some execs out and new ones in, plus pay changes.
AI Summary
Karyopharm Therapeutics Inc. announced on January 27, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for its officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — Board and executive changes can indicate internal shifts or strategic realignments that may carry inherent risks.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Registrant
- January 27, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 85 Wells Avenue, 2nd Floor Newton, Massachusetts 02459 (address) — Principal Executive Offices
- (617) 658-0600 (phone_number) — Registrant's telephone number
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates the departure of certain officers and directors but does not specify the exact roles in this summary.
Who are the newly elected directors?
The filing states that directors have been elected but does not name them in this summary.
What are the details of the compensatory arrangements for certain officers?
The filing mentions adjustments to compensatory arrangements but does not provide specific details in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on January 27, 2025.
What is Karyopharm Therapeutics Inc.'s state of incorporation?
Karyopharm Therapeutics Inc. is incorporated in Delaware.
Filing Stats: 715 words · 3 min read · ~2 pages · Grade level 15.4 · Accepted 2025-01-31 16:05:27
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
Filing Documents
- d914351d8k.htm (8-K) — 24KB
- 0001193125-25-018385.txt ( ) — 143KB
- kpti-20250127.xsd (EX-101.SCH) — 3KB
- kpti-20250127_lab.xml (EX-101.LAB) — 18KB
- kpti-20250127_pre.xml (EX-101.PRE) — 11KB
- d914351d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: January 31, 2025 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary